The American journal of the medical sciences最新文献

筛选
英文 中文
Associations between serum uric acid and breast cancer incidence: A systematic review and meta-analysis. 血清尿酸与乳腺癌发病率之间的关系:系统回顾和荟萃分析。
The American journal of the medical sciences Pub Date : 2024-07-08 DOI: 10.1016/j.amjms.2024.07.005
Xiao Xue, Zhengyi Sun, Xufeng Ji, Hua Lin, Huang Jing, Qiuyang Yu
{"title":"Associations between serum uric acid and breast cancer incidence: A systematic review and meta-analysis.","authors":"Xiao Xue, Zhengyi Sun, Xufeng Ji, Hua Lin, Huang Jing, Qiuyang Yu","doi":"10.1016/j.amjms.2024.07.005","DOIUrl":"10.1016/j.amjms.2024.07.005","url":null,"abstract":"<p><strong>Background: </strong>Serum uric acid (SUA) may be involved in the development of cancer by inhibiting oxidative stress, but its relationship with breast cancer remains unclear.</p><p><strong>Materials and methods: </strong>The PubMed, Embase, and Web of Science databases were searched systematically for studies on SUA levels in women with breast cancer and the effect of SUA levels on the risk of breast cancer. The Newcastle‒Ottawa Quality Assessment Scale (NOS) was used to assess the quality of all relevant studies included.</p><p><strong>Results: </strong>A total of 19 studies were included, including 75,827 women with breast cancer and 508,528 healthy controls. A meta-analysis found that SUA levels were negatively correlated with breast cancer risk in women (HR = 0.94, 95% CI: 0.89 - 0.99, p = 0.003). SUA levels in female breast cancer patients were not significantly different from those in healthy controls (SMD = 0.49, 95% CI = -0.09 - 1.08, p = 0.10), while SUA levels were increased in female breast cancer patients in articles published after 2010, SUA concentration detected by spectrophotometry, and non-Asian populations, regardless of menopausal state and treatment state.</p><p><strong>Conclusion: </strong>High levels of SUA may reduce the risk of breast cancer in women, suggesting that SUA was a protective factor in women.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis. GLP-1 受体激动剂和 SGLT-2 抑制剂联合或单药治疗 2 型糖尿病的有效性和安全性:最新系统综述与 Meta 分析》。
The American journal of the medical sciences Pub Date : 2024-07-06 DOI: 10.1016/j.amjms.2024.07.011
Adili Tuersun, Guanxin Hou, Gang Cheng
{"title":"Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.","authors":"Adili Tuersun, Guanxin Hou, Gang Cheng","doi":"10.1016/j.amjms.2024.07.011","DOIUrl":"10.1016/j.amjms.2024.07.011","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of combination therapy with sodium-glucose cotransporter2(SGLT-2) inhibitors and glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>To construct an exhaustive database of randomized controlled trials (RCTs) concerning SGLT-2 inhibitors and GLP-1 agonists, a methodical search was undertaken across a range of databases, such as Embase, PubMed, and the Cochrane Central Register of Controlled Trials, from their inception to January 2023. Following this, a meta-analysis was executed to amalgamate the collected data, which allowed for the calculation of standardized mean differences (SMDs), odds ratios (ORs), and 95 % confidence intervals (CIs) for a spectrum of outcomes. This analytical approach was designed to yield a quantitative evaluation of the therapeutic efficacy and safety profile of SGLT-2 inhibitors and GLP-1 agonists for the treatment of diabetes mellitus.</p><p><strong>Results: </strong>When compared to GLP-1 agonist therapy alone, the combination therapy did not significantly reduce fasting plasma glucose (FPG) levels (95 % confidence interval [CI]: -0.27, 0.10; p = 0.35), body weight (95 % CI: -0.18, 0.18; p = 1.00), Glycosylated Hemoglobin, Type A1C (HbA1c) (95 % CI: -0.29, 0.07; p = 0.22), or systolic blood pressure (SBP) values (95 % CI: -0.29, 0.06; p = 0.21). In contrast, when compared to SGLT-2 inhibitor therapy alone, combination therapy significantly decreased FPG by 0.24 mmol/L (95 % CI: -0.43, -0.05; p = 0.01), HbA1c by 0.45 % (95 % CI: -0.72, -0.18; p = 0.001), and SBP by 0.12 mmHg (95 % CI: -0.24, 0.00; p = 0.05). However, the combination therapy failed to demonstrate a significant reduction in body weight when compared with either SGLT-2 inhibitor therapy (95 % CI: -0.20, 0.05; p = 0.24) or GLP-1 agonist therapy (95 % CI: -0.18, 0.18; p = 1.00). Additionally, the combination therapy did not increase the incidence of hypoglycemia. It should be noted that data regarding mortality and cardiovascular outcomes were limited.</p><p><strong>Conclusions: </strong>The combination treatment of SGLT-2 inhibitors and GLP-1 receptor agonists effectively reduces HbA1c, FPG, and SBP without elevating the risk of hypoglycemia when compared to monotherapy with SGLT-2 inhibitors. However, these beneficial effects were not observed when the combination therapy was compared with GLP-1 receptor agonist treatment alone.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term trends in lifestyle factors among respondents with dyslipidemia in the United States. 美国血脂异常受访者生活方式因素的长期趋势。
The American journal of the medical sciences Pub Date : 2024-07-05 DOI: 10.1016/j.amjms.2024.06.025
Bingqing Bai, Quanjun Liu, Yuting Liu, Fengyao Liu, Yu Wang, Yilin Chen, Yanting Liang, Haochen Wang, Chao Wu, Lan Guo, Huan Ma, Qingshan Geng
{"title":"Long-term trends in lifestyle factors among respondents with dyslipidemia in the United States.","authors":"Bingqing Bai, Quanjun Liu, Yuting Liu, Fengyao Liu, Yu Wang, Yilin Chen, Yanting Liang, Haochen Wang, Chao Wu, Lan Guo, Huan Ma, Qingshan Geng","doi":"10.1016/j.amjms.2024.06.025","DOIUrl":"10.1016/j.amjms.2024.06.025","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the long-term trends in unhealthy lifestyle factors and the risk sociodemographic subgroups among people with dyslipidemia.</p><p><strong>Methods: </strong>Data extracted from the 1999 to 2018 National Health and Nutrition Examination Survey (NHANES). Lifestyle factors were smoking status, alcohol drinking, obesity, dietary quality, depression, physical activity, and sedentary behavior. A Joinpoint regression model was used to estimate trends in the log-transformed age-standardized prevalence. Multinomial logistic regression models adjusted for age, sex, and race/ethnicity were used to analyze subgroups by sociodemographic factors.</p><p><strong>Results: </strong>Data for 33,680 respondents were extracted between 1999 and 2018. The prevalence of smoking and poor-quality diet decreased from 1999 to 2018 (P<0.001), while obesity significantly increased (P<0.001). The prevalence of depression marginally increased from 2005 to 2018 (P=0.074). We observed that non-Hispanic Black individuals, Hispanics, males, as well as those with lower family income-to-poverty ratios and education levels, unemployed individuals, or those lacking a spouse/live-in partner, were at elevated risk of unhealthy lifestyle factors when compared to the reference groups.</p><p><strong>Conclusions: </strong>Among NHANES respondents from 1999 to 2018 with dyslipidemia, significant reductions in the prevalence of current smoking and poor diet were observed, while the prevalence of obesity was markedly increased. There were sociodemographic differences in the management of lifestyle factors. Further initiatives to encourage people with dyslipidemia are required to reduce potential adverse outcomes.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single nucleotide polymorphisms of GEMIN3 modify the risk of primary Sjögren's syndrome in female patients. GEMIN3 的单核苷酸多态性改变了女性患者罹患原发性斯约格伦综合征的风险。
The American journal of the medical sciences Pub Date : 2024-07-04 DOI: 10.1016/j.amjms.2024.07.001
Dong Wang, Jingjing Zhang, Yufei Zhao, Ruijie Cao, Yingnan Wang, Iren Guo, Chenxing Peng, Yanrong Song, Shasha Zhang
{"title":"Single nucleotide polymorphisms of GEMIN3 modify the risk of primary Sjögren's syndrome in female patients.","authors":"Dong Wang, Jingjing Zhang, Yufei Zhao, Ruijie Cao, Yingnan Wang, Iren Guo, Chenxing Peng, Yanrong Song, Shasha Zhang","doi":"10.1016/j.amjms.2024.07.001","DOIUrl":"10.1016/j.amjms.2024.07.001","url":null,"abstract":"<p><strong>Background: </strong>MicroRNA (miRNA)-processing machinery may modify the risk of primary Sjögren's syndrome (pSS) by altering miRNA expression profiles. Inflammatory cytokines and reactive oxygen species (ROS) are also involved in pSS; however, the role of altered miRNAs expression in its pathogenesis is still unclear. We aimed to evaluate the relationship between single-nucleotide polymorphisms (SNPs) in miRNA processing machinery genes, including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348), and the risk of pSS in female patients. The potential associations of cytokines and ROS with pSS-susceptible SNPs were also evaluated.</p><p><strong>Materials and methods: </strong>The SNPs confirmed by polymerase chain reaction ligase detection reaction were genotyped in 74 female patients with pSS and 77 controls. The relationship was analyzed by Student's t-test, Wilcoxon rank-sum test, chi-square test, Pearson's correlation test, and binary logistic regression analysis.</p><p><strong>Results: </strong>For rs197412 of the GEMIN3 gene, the genotype TT carrier was associated with a 2.172-fold increased risk for pSS when compared with that of CT+CC carrier (odds ratio: 2.172, 95% CI, 1.133-4.166, p=0.019). Simultaneously, the pSS-susceptible TT carriers were associated with increased interferon-γ (IFN-γ) (P < 0.001) and tumor necrosis factor-α (TNF-α) (P = 0.003) levels when compared with that of CT+CC genotype carriers in female patients with pSS. The subsequent analysis also showed a weak positive correlation between IFN-γ and TNF-α levels (r=0.271, P = 0.019).</p><p><strong>Conclusion: </strong>The predictors of GEMIN3 SNPs might modify pSS development in females by mediating the expression of miRNAs and therefore regulate the levels of IFN-γ and TNF-α.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pamiparib, a novel intervention with anti-neoplastic activity for the treatment of glioblastoma. 帕米帕利(Pamiparib),一种具有抗肿瘤活性的治疗胶质母细胞瘤的新型干预方法。
The American journal of the medical sciences Pub Date : 2024-07-03 DOI: 10.1016/j.amjms.2024.07.007
Sehar Ul Duaa, Eeshal Fatima, Zaheer Qureshi
{"title":"Pamiparib, a novel intervention with anti-neoplastic activity for the treatment of glioblastoma.","authors":"Sehar Ul Duaa, Eeshal Fatima, Zaheer Qureshi","doi":"10.1016/j.amjms.2024.07.007","DOIUrl":"10.1016/j.amjms.2024.07.007","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitor-related changes consistent with paradoxical pulse 与矛盾脉搏一致的监护仪相关变化
The American journal of the medical sciences Pub Date : 2024-07-01 DOI: 10.1016/j.amjms.2024.07.014
Hiroki Matsuura, Masayuki Kishida
{"title":"Monitor-related changes consistent with paradoxical pulse","authors":"Hiroki Matsuura, Masayuki Kishida","doi":"10.1016/j.amjms.2024.07.014","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.07.014","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare observation in a case of Williams-Campbell syndrome. 威廉姆斯-坎贝尔综合症病例中的罕见观察结果。
The American journal of the medical sciences Pub Date : 2024-06-29 DOI: 10.1016/j.amjms.2024.06.031
Chun Ian Soo, Wai Ling Leong, Leng Cheng Sia
{"title":"A rare observation in a case of Williams-Campbell syndrome.","authors":"Chun Ian Soo, Wai Ling Leong, Leng Cheng Sia","doi":"10.1016/j.amjms.2024.06.031","DOIUrl":"10.1016/j.amjms.2024.06.031","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease. 代谢功能障碍相关性脂肪肝与动脉粥样硬化性心血管疾病之间的关系。
The American journal of the medical sciences Pub Date : 2024-06-27 DOI: 10.1016/j.amjms.2024.06.022
Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng
{"title":"Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease.","authors":"Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng","doi":"10.1016/j.amjms.2024.06.022","DOIUrl":"10.1016/j.amjms.2024.06.022","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome and remains a major global health burden. The increased prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide has contributed to the rising incidence of NAFLD. It is widely believed that atherosclerotic cardiovascular disease (ASCVD) is associated with NAFLD. In the past decade, the clinical implications of NAFLD have gone beyond liver-related morbidity and mortality, with a majority of patient deaths attributed to malignancy, coronary heart disease (CHD), and other cardiovascular (CVD) complications. To better define fatty liver disease associated with metabolic disorders, experts proposed a new term in 2020 - metabolic dysfunction associated with fatty liver disease (MAFLD). Along with this new designation, updated diagnostic criteria were introduced, resulting in some differentiation between NAFLD and MAFLD patient populations, although there is overlap. The aim of this review is to explore the relationship between MAFLD and ASCVD based on the new definitions and diagnostic criteria, while briefly discussing potential mechanisms underlying cardiovascular disease in patients with MAFLD.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of atypical Pulmonary Tuberculosis without typical clinical features diagnosed by pathology. 通过病理学诊断的无典型临床特征的非典型肺结核的特征。
The American journal of the medical sciences Pub Date : 2024-06-26 DOI: 10.1016/j.amjms.2024.06.023
Xi Wang, Dandan Zhang, Qiuxia Sun, Yan You, Jian Lan
{"title":"Characteristics of atypical Pulmonary Tuberculosis without typical clinical features diagnosed by pathology.","authors":"Xi Wang, Dandan Zhang, Qiuxia Sun, Yan You, Jian Lan","doi":"10.1016/j.amjms.2024.06.023","DOIUrl":"10.1016/j.amjms.2024.06.023","url":null,"abstract":"<p><strong>Purpose: </strong>Some patients with pulmonary tuberculosis (PTB) do not display typical clinical features, leading to delays in diagnosis and treatment.</p><p><strong>Methods: </strong>We retrospectively analyzed PTB patients admitted to the Second Affiliated Hospital of Chongqing Medical University between 2017 and 2020. They are divided into pathological group (diagnosed through pathological biopsy) and control group (diagnosed via sputum or lavage fluid). Clinical data of both groups were compared. Based on radiographic features, the pathological group was further divided into the inflammation group, peripheral nodule group, and central occupancy group. We then statistically analyzed the computed tomography (CT) signs, bronchoscopic manifestations and results of pathological biopsy for each subgroup.</p><p><strong>Results: </strong>The pathological group consisted of 75 patients, while the control group had 338 patients. Multivariate logistic regression analysis showed that the pathological group had more diabetes (OR = 3.266, 95% CI = 1.609-6.630, P = 0.001), lower ESR (OR = 0.984, 95% CI = 0.971-0.998, P = 0.022), and lower CRP (OR = 0.990, 95% CI = 0.980-0.999, P = 0.036). In the three subgroups, the exudative lesions in the inflammation group were mostly located in atypical areas of PTB. The lobulation sign and spiculation sign were frequently observed in the peripheral nodule group. All presented with significant hilar mediastinal lymphadenopathy in the central occupancy group. In the pathological group, bronchoscopic manifestations typically included mucosal edema and bronchial stenosis.</p><p><strong>Conclusion: </strong>Diabetes is an independent risk factor for atypical PTB. Expression of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in atypical PTB is low. Radiologically, it is most easily misdiagnosed when presented as peripheral solid nodules or masses, so a biopsy is recommended.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-guided lumbar sympathetic nerve block for an intractable abdominal pain and intestinal obstruction. 超声引导下腰部交感神经阻滞治疗顽固性腹痛和肠梗阻。
The American journal of the medical sciences Pub Date : 2024-06-25 DOI: 10.1016/j.amjms.2024.06.021
Heyu Ji, Di Xia, Xulei Cui, Yuguang Huang
{"title":"Ultrasound-guided lumbar sympathetic nerve block for an intractable abdominal pain and intestinal obstruction.","authors":"Heyu Ji, Di Xia, Xulei Cui, Yuguang Huang","doi":"10.1016/j.amjms.2024.06.021","DOIUrl":"10.1016/j.amjms.2024.06.021","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信